Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia

Pasquale W Benedetto, R. Mertelsmann, T. H. Szatrowski, M. Andreeff, T. Gee, Z. Arlin, S. Kempin, B. Clarkson

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Bone marrow and/or peripheral blood samples from 133 (75%) of a total of 177 consecutive previously untreated protocol patients with acute nonlymphoblastic leukemia (ANLL) were analyzed for terminal deoxynucleotidyl transferase (TdT) activity at the time of presentation. Twenty-nine (22%) were found to exhibit TdT activity (≥ 0.10 U/108 cells, TdT+) as measured in a biochemical microassay. There were no differences between TdT+ as compared with TdT-negative (TdT-) patients with respect to age, sex, French-American-British (FAB) classification, or the presence of Auer's rods. Remission induction rates were higher for the TdT- patients, with 68% v 48% for the TdT+ patients (P = .05). TdT- patients also experienced longer remissions (P = .003) than TdT+ patients, especially in the Auer's rod-positive subgroup (P = .002). None of five patients with TdT+ ANLL treated with vincristine and prednisone as initial therapy achieved complete remission; all required induction regimens containing daunorubicin or amsacrine in combination with cytosine arabinoside and 6-thioguanine. It is concluded that TdT activity in ANLL indicates biphenotypia or lineage infidelity and is associated with a poor prognosis on chemotherapy protocols currently used for the treatment of ANLL.

Original languageEnglish
Pages (from-to)489-495
Number of pages7
JournalJournal of Clinical Oncology
Volume4
Issue number4
StatePublished - Jul 30 1986
Externally publishedYes

Fingerprint

DNA Nucleotidylexotransferase
Acute Myeloid Leukemia
Amsacrine
Thioguanine
Remission Induction
Daunorubicin
Cytarabine
Vincristine
Prednisone
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Benedetto, P. W., Mertelsmann, R., Szatrowski, T. H., Andreeff, M., Gee, T., Arlin, Z., ... Clarkson, B. (1986). Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia. Journal of Clinical Oncology, 4(4), 489-495.

Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia. / Benedetto, Pasquale W; Mertelsmann, R.; Szatrowski, T. H.; Andreeff, M.; Gee, T.; Arlin, Z.; Kempin, S.; Clarkson, B.

In: Journal of Clinical Oncology, Vol. 4, No. 4, 30.07.1986, p. 489-495.

Research output: Contribution to journalArticle

Benedetto, PW, Mertelsmann, R, Szatrowski, TH, Andreeff, M, Gee, T, Arlin, Z, Kempin, S & Clarkson, B 1986, 'Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia', Journal of Clinical Oncology, vol. 4, no. 4, pp. 489-495.
Benedetto, Pasquale W ; Mertelsmann, R. ; Szatrowski, T. H. ; Andreeff, M. ; Gee, T. ; Arlin, Z. ; Kempin, S. ; Clarkson, B. / Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 4. pp. 489-495.
@article{800e7ba7fb31491c8a5339a0e3495b05,
title = "Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia",
abstract = "Bone marrow and/or peripheral blood samples from 133 (75{\%}) of a total of 177 consecutive previously untreated protocol patients with acute nonlymphoblastic leukemia (ANLL) were analyzed for terminal deoxynucleotidyl transferase (TdT) activity at the time of presentation. Twenty-nine (22{\%}) were found to exhibit TdT activity (≥ 0.10 U/108 cells, TdT+) as measured in a biochemical microassay. There were no differences between TdT+ as compared with TdT-negative (TdT-) patients with respect to age, sex, French-American-British (FAB) classification, or the presence of Auer's rods. Remission induction rates were higher for the TdT- patients, with 68{\%} v 48{\%} for the TdT+ patients (P = .05). TdT- patients also experienced longer remissions (P = .003) than TdT+ patients, especially in the Auer's rod-positive subgroup (P = .002). None of five patients with TdT+ ANLL treated with vincristine and prednisone as initial therapy achieved complete remission; all required induction regimens containing daunorubicin or amsacrine in combination with cytosine arabinoside and 6-thioguanine. It is concluded that TdT activity in ANLL indicates biphenotypia or lineage infidelity and is associated with a poor prognosis on chemotherapy protocols currently used for the treatment of ANLL.",
author = "Benedetto, {Pasquale W} and R. Mertelsmann and Szatrowski, {T. H.} and M. Andreeff and T. Gee and Z. Arlin and S. Kempin and B. Clarkson",
year = "1986",
month = "7",
day = "30",
language = "English",
volume = "4",
pages = "489--495",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia

AU - Benedetto, Pasquale W

AU - Mertelsmann, R.

AU - Szatrowski, T. H.

AU - Andreeff, M.

AU - Gee, T.

AU - Arlin, Z.

AU - Kempin, S.

AU - Clarkson, B.

PY - 1986/7/30

Y1 - 1986/7/30

N2 - Bone marrow and/or peripheral blood samples from 133 (75%) of a total of 177 consecutive previously untreated protocol patients with acute nonlymphoblastic leukemia (ANLL) were analyzed for terminal deoxynucleotidyl transferase (TdT) activity at the time of presentation. Twenty-nine (22%) were found to exhibit TdT activity (≥ 0.10 U/108 cells, TdT+) as measured in a biochemical microassay. There were no differences between TdT+ as compared with TdT-negative (TdT-) patients with respect to age, sex, French-American-British (FAB) classification, or the presence of Auer's rods. Remission induction rates were higher for the TdT- patients, with 68% v 48% for the TdT+ patients (P = .05). TdT- patients also experienced longer remissions (P = .003) than TdT+ patients, especially in the Auer's rod-positive subgroup (P = .002). None of five patients with TdT+ ANLL treated with vincristine and prednisone as initial therapy achieved complete remission; all required induction regimens containing daunorubicin or amsacrine in combination with cytosine arabinoside and 6-thioguanine. It is concluded that TdT activity in ANLL indicates biphenotypia or lineage infidelity and is associated with a poor prognosis on chemotherapy protocols currently used for the treatment of ANLL.

AB - Bone marrow and/or peripheral blood samples from 133 (75%) of a total of 177 consecutive previously untreated protocol patients with acute nonlymphoblastic leukemia (ANLL) were analyzed for terminal deoxynucleotidyl transferase (TdT) activity at the time of presentation. Twenty-nine (22%) were found to exhibit TdT activity (≥ 0.10 U/108 cells, TdT+) as measured in a biochemical microassay. There were no differences between TdT+ as compared with TdT-negative (TdT-) patients with respect to age, sex, French-American-British (FAB) classification, or the presence of Auer's rods. Remission induction rates were higher for the TdT- patients, with 68% v 48% for the TdT+ patients (P = .05). TdT- patients also experienced longer remissions (P = .003) than TdT+ patients, especially in the Auer's rod-positive subgroup (P = .002). None of five patients with TdT+ ANLL treated with vincristine and prednisone as initial therapy achieved complete remission; all required induction regimens containing daunorubicin or amsacrine in combination with cytosine arabinoside and 6-thioguanine. It is concluded that TdT activity in ANLL indicates biphenotypia or lineage infidelity and is associated with a poor prognosis on chemotherapy protocols currently used for the treatment of ANLL.

UR - http://www.scopus.com/inward/record.url?scp=0022644622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022644622&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 489

EP - 495

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -